Related Experiment Video

Updated: Dec 24, 2025

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level
06:02

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level

Published on: November 2, 2020

6.1K

Non-coding RNAs and Pathological Cardiac Hypertrophy

Jianfeng He1, Yanhong Luo1, Junxia Song1

  • 1Children's Hospital Chongqing Medical University, Chongqing, People's Republic of China.

Advances in Experimental Medicine and Biology
|April 15, 2020
PubMed

Insights

Non-coding RNAs (ncRNAs) are implicated in myocardial hypertrophy (MH), a key factor in cardiovascular disease (CVD). Understanding ncRNA roles in intercellular communication via extracellular vesicles (EVs) offers new diagnostic and therapeutic targets for CVD.

Area of Science:

  • Cardiology
  • Molecular Biology
  • Genetics

Background:

  • Cardiovascular disease (CVD) presents significant global health challenges due to high prevalence, disability, and mortality.
  • Myocardial hypertrophy (MH) is a critical pathological process in various cardiovascular diseases and an independent risk factor for adverse cardiovascular outcomes.
  • Non-coding RNAs (ncRNAs) are increasingly recognized for their regulatory roles in human pathophysiological processes.

Purpose of the Study:

  • To explore the role of non-coding RNAs (ncRNAs) in the development of myocardial hypertrophy (MH).
  • To investigate the significance of intercellular communication mediated by extracellular vesicles (EVs) in the context of MH.
  • To identify ncRNAs as potential diagnostic markers and therapeutic targets for cardiovascular diseases.

Main Methods:

  • Analysis of abnormal ncRNA expression in cardiac cells associated with pathological cardiac hypertrophy.
  • Investigation of ncRNA involvement in intercellular communication through extracellular vesicles (EVs).
  • Examination of regulatory interactions between ncRNAs and other molecules in cardiac hypertrophy.

Main Results:

  • Abnormal ncRNA expression is linked to pathological cardiac hypertrophy in different cardiac cell types.
  • Extracellular vesicles (EVs) mediate intercellular communication involving ncRNAs relevant to MH.
  • ncRNAs interact with other molecules, influencing the occurrence and progression of cardiac hypertrophy.

Conclusions:

  • ncRNAs play a crucial role in the pathogenesis of myocardial hypertrophy.
  • ncRNA-mediated intercellular communication via EVs presents novel avenues for early clinical diagnosis of cardiovascular disease.
  • Targeting ncRNAs offers potential for precise therapeutic strategies in managing myocardial hypertrophy and cardiovascular disease.

Keywords:
Extracellular vesiclesMyocardial hypertrophyNon-coding RNA

More Related Videos

Tissue-specific miRNA Expression Profiling in Mouse Heart Sections Using In Situ Hybridization08:22

Tissue-specific miRNA Expression Profiling in Mouse Heart Sections Using In Situ Hybridization

Published on: September 15, 2018

8.5K
Isolation, Culture, and Functional Characterization of Adult Mouse Cardiomyoctyes12:49

Isolation, Culture, and Functional Characterization of Adult Mouse Cardiomyoctyes

Published on: September 24, 2013

25.1K

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
283
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
594
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
413
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
366
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.6K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.6K